Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com
StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a research note issued to investors on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 price target on shares of Minerva Neurosciences in a research note on […]
StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a research note issued to investors on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 price target on shares of Minerva Neurosciences in a research note on […]
